Jaguar Health Files 8-K: Stock, Bylaws, and Agreements Updated

TL;DR

Jaguar Health updated its bylaws and agreements, affecting shareholder rights. Big changes coming.

AI Summary

On May 17, 2024, Jaguar Health, Inc. entered into a Material Definitive Agreement related to its common stock. The company also made modifications to the rights of its security holders and amended its articles of incorporation or bylaws. These actions are part of the company's ongoing corporate governance and financial strategy.

Why It Matters

This filing indicates significant corporate actions by Jaguar Health, Inc., potentially impacting shareholder rights and the company's operational structure.

Risk Assessment

Risk Level: medium — Filings detailing material definitive agreements and modifications to security holder rights can introduce uncertainty and potential shifts in the company's financial and operational landscape.

Key Numbers

• 001-36714 — SEC File Number (Identifies the specific filing for Jaguar Health, Inc.)
• 46-2956775 — IRS Employer Identification No. (Tax identification number for Jaguar Health, Inc.)

Key Players & Entities

• Jaguar Health, Inc. (company) — Registrant
• May 17, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 200 Pine Street, Suite 400 (address) — Business and mailing address
• San Francisco, CA (location) — City and State of business address

FAQ

Key Financial Figures

• $0.0001 — h registered Common Stock, Par Value $0.0001 Per Share JAGX The Nasdaq Capital Mar
• $75,000,000 — the Second ATM Amendment, the previous $75,000,000 limit on the aggregate offering amount

Filing Documents

• tm2415080d1_8k.htm (8-K) — 35KB
• tm2415080d1_ex3-1.htm (EX-3.1) — 9KB
• tm2415080d1_ex5-1.htm (EX-5.1) — 11KB
• tm2415080d1_ex10-1.htm (EX-10.1) — 18KB
• tm2415080d1_ex99-1.htm (EX-99.1) — 12KB
• tm2415080d1_ex5-1img001.jpg (GRAPHIC) — 6KB
• tm2415080d1_ex99-1img001.jpg (GRAPHIC) — 12KB
• 0001104659-24-064484.txt ( ) — 303KB
• jagx-20240517.xsd (EX-101.SCH) — 3KB
• jagx-20240517_lab.xml (EX-101.LAB) — 33KB
• jagx-20240517_pre.xml (EX-101.PRE) — 22KB
• tm2415080d1_8k_htm.xml (XML) — 4KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On May 23, 2024, Jaguar Health, Inc. (the "Company") entered into an amendment (the "Second ATM Amendment") to that certain At the Market Offering Agreement, dated December 10, 2021 (as amended by that certain amendment on February 2, 2022, and by the Second ATM Amendment, the "Agreement"), between the Company and Ladenburg Thalmann & Co. Inc., as agent ("Ladenburg"). Pursuant to the Second ATM Amendment, the previous $75,000,000 limit on the aggregate offering amount of shares of the Company's common stock, $0.0001 par value per share (the "Shares"), which the Company may sell and issue through Ladenburg, as the sales agent, was removed such that the amount issuable under the Agreement is limited solely by certain limitations as specified in the Second ATM Amendment. Also on May 23, 2024, the Company filed a prospectus supplement with the Securities and Exchange Commission (the "Prospectus Supplement") in connection with the offer and sale of the Shares pursuant to the Agreement. The issuance and sale of the Shares by the Company under the Agreement will be made pursuant to the Company's registration statement on Form S-3 (File No. 333-278861) filed with the SEC on April 22, 2024 and declared effective on May 1, 2024 (the "Registration Statement"), as supplemented by a prospectus supplement dated May 23, 2024. The opinion of Reed Smith LLP, the Company's counsel, regarding the legality of the Shares that may be issued pursuant to the Agreement, is filed herewith as Exhibit 5.1. The Shares will be sold pursuant to the Registration Statement, and offerings of the Shares will be made only by means of the Prospectus Supplement and the accompanying prospectus. This Current Report on Form 8-K shall not constitute an offer to sell or solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to

03 Material Modification to Rights of Security Holders

Item 3.03 Material Modification to Rights of Security Holders. To the extent required by Item 3.03 of Form 8-K, the information regarding the Reverse Stock Split (as defined below) contained in Item 5.03 of this Current Report on Form 8-K is incorporated by reference herein.

03 Amendment to Articles of Incorporation

Item 5.03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year. As previously disclosed, at the special meeting of stockholders of the Company held on April 9, 2024 (the "Special Meeting"), the Company's stockholders approved an amendment (the "Eighth Amendment") to the Company's Third Amended and Restated Certificate of Incorporation, as amended (the "COI"), to effect a reverse stock split of the Company's voting common stock ("Common Stock") at a ratio of not less than one-for-two and not greater than one-for-one hundred fifty, with the exact ratio within that range to be determined in the discretion of the Company's board of directors (the "Board") on or before January 22, 2025. Pursuant to such authority granted by the Company's stockholders, the Board approved a one-for-sixty (60) reverse stock split (the "Reverse Stock Split") of the Common Stock , and on May 17, 2024, the Company filed the Eighth Amendment with the Secretary of State of the State of Delaware. The Reverse Stock Split will become effective in accordance with the terms of the Eighth Amendment at 12:01 am Eastern Time on May 23, 2024 (the "Effective Time"). When the Reverse Stock Split becomes effective, every sixty (60) shares of the Company's issued and outstanding Common Stock immediately prior to the Effective Time shall automatically be reclassified into one (1) share of Common Stock, without any change in the par value per share. The Reverse Stock Split reduces the number of shares of Common Stock issuable upon the conversion of the Company's outstanding non-voting common stock and the exercise or vesting of its outstanding stock options and warrants in proportion to the ratio of the Reverse Stock Split and causes a proportionate increase in the conversion and exercise prices of such non-voting common stock, stock options and warrants. In addition, the number of shares reserved for issuance under the Company's equity compensation plans immediately prior to the Effectiv

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On May 17, 2024, the Company issued a press release announcing the effectuation of the Reverse Stock Split, a copy of which is furnished as Exhibit 99.1. The information in Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, or incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Certificate of Eighth Amendment of the Third Amended and Restated Certificate of Incorporation of Jaguar Health, Inc. 5.1 Opinion of Reed Smith LLP as to the legality of the Shares. 10.1 Second Amendment to the At the Market Offering Agreement, dated May 23, 2024, by and between Jaguar Health, Inc. and Ladenburg Thalmann & Co. Inc. 99.1 Press Release Announcing Reverse Stock Split dated May 17, 2024. 104 Cover Page Interactive Data File (embedded within the inline XBRL document) 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JAGUAR HEALTH, INC. By: /s/ Lisa A. Conte Name: Lisa A. Conte Title: Chief Executive Officer & President Date: May 23, 2024 4